// App-Quantinova.ai

: Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Researchers

Presenter

  • Kristy Drafahl

Principal Investigators

  • David C Smith

  • Cristen Graham

  • Christine Glynn

  • Cindy Spittle

  • Scott Verrow

  • Victor M. Rivera

  • Shouryadeep Srivastava

  • Kevin Hawkins

  • Chad Galderisi

Medical Centers

  • MolecularMD Corp., Portland, OR.

  • Millennium Pharmaceuticals, Inc., Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Ponatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03589326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved